Turning Point Brands earnings date
Want to see TPB full AI Analyst Report?
Turning Point Brands (TPB) Q3 2026 Earnings Report
TPB Q3 2026 EPS Results
- Actual EPS
- $0.19
- Consensus EPS
- $0.20
- Beat/Miss
- Missed by -$0.01
- One Year Ago EPS
- $1.13
TPB Q3 2026 Revenue Results
- Actual Revenue
- $151.10M
- Expected Revenue
- $146.68M
- Beat/Miss
- Beat by +$4.42M
- YoY Revenue Growth
- +26.99%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/09/2026
- Time
- Before Open
- Conference Call
- Monday, November 9, 2026
Turning Point Brands's next earnings date is estimated for February 25, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was predominantly positive. Modern Oral delivered triple-digit year-over-year growth, distribution expanded rapidly, FRE and ALP showed encouraging retail momentum, liquidity remained strong, and full-year guidance was maintained. The main negatives were the 41% year-over-year adjusted EBITDA decline, lower Zig-Zag sales, Stoker's gross-margin contraction, and uncertainty around fourth-quarter timing and FDA-dependent manufacturing commencement.
The company remains confident in achieving its full year outlook provided on September 21, 2026: Modern Oral gross sales guidance is $330 million to $350 million, net sales guidance is $260 million to $270 million, and full year adjusted EBITDA guidance is $70 million to $80 million; it continues to expect an effective income tax rate between 23% to 26% on a go-forward basis, fourth quarter CapEx of $1 million to $2 million excluding projects related to Modern Oral, and roughly $3.5 million of fourth quarter spending in support of its PMTA. The company is on track to increase its chain store count by more than 70% during 2026 and currently expects U.S. manufacturing to commence in 2027.
- Strong Consolidated Revenue GrowthThird-quarter net sales increased 27.0% year-over-year to $151 million, driven primarily by Modern Oral. Gross profit increased 21% to $85 million.
- Modern Oral Revenue SurgeModern Oral gross sales increased 114% year-over-year and 8% sequentially, while net sales increased 103% year-over-year and 9% sequentially. Modern Oral represented 49% of total revenue, up from 31% in Q3 2025.
- FRE and ALP Brand MomentumManagement reported encouraging performance from both FRE and ALP, with continued consumer adoption, positive early results in newly added retail locations, and strong performance in direct-to-consumer, independent retail, and chain-account channels.
- Expanding Chain DistributionThe company is on track to increase its chain store count by more than 70% during 2026. FRE is expanding across national retail chains, while ALP is expanding across independent retailers and regional chains and beginning discussions with larger national chains.
- Positive Retail Velocity and Assortment TrendsManagement said velocity is encouraging for both FRE and ALP, with better velocity in stores carrying more SKUs. In several chain accounts, improving velocity and share performance have supported increased assortments over time. Early ALP brick-and-mortar results were described as meeting or exceeding expectations.
- Strong Stoker's Segment PerformanceStoker's segment net sales increased 52.0% year-over-year to $114 million and represented 75% of consolidated net sales. Heritage Stoker's brand net revenue increased 3% to $39.0 million, driven by continued share growth in MST, while Stoker's gross profit increased 42% to $64 million.
- MST Category OutperformanceThe Stoker's MST business continued to outperform the category, with continued share growth partially offsetting anticipated declines in loose leaf.
- Progress on Commercial and Brand-Building InitiativesThe company continued investing in sales-force expansion, retail execution, strategic partnerships, targeted campaigns, product innovation, and in-store merchandising. FRE Labs introduced limited-edition flavors, while ALP's New Frontier Collection introduced three requested flavors.
- Zig-Zag Brand Development EffortsThe company remains focused on strengthening Zig-Zag's core rolling papers business, accelerating growth in cones and wraps, and expanding brand relevance through strategic partnerships, targeted media investments, and consumer engagement.
- Domestic Manufacturing PreparationU.S. manufacturing is currently expected to commence in 2027. The company is upgrading its facility and recently added equipment intended to support greater efficiencies, while the applications needed to get the Louisville facility operating have been submitted and completed.
- PMTA Dual-Track StrategyFollowing revised FDA guidance in May, the company is preparing a second PMTA submission that will list U.S. manufacturing as the primary manufacturing site while keeping the existing PMTA in the queue without altering its manufacturing site.
- Maintained Full-Year GuidanceThe company maintained its full-year guidance for Modern Oral gross sales of $330 million to $350 million, Modern Oral net sales of $260 million to $270 million, and adjusted EBITDA of $70 million to $80 million. It also maintained an expected effective income tax rate of 23% to 26%.
- Liquidity and Share RepurchaseThird-quarter free cash flow was $3.5 million, and the company ended the quarter with $251 million of cash. It repurchased $10.0 million of stock during the quarter and said it continues to evaluate buybacks opportunistically.
- Positive Outlook for Category ConsolidationManagement said the nicotine pouch category is beginning to mature, with fewer players expected as smaller competitors are weeded out. It believes FRE and ALP have a strong opportunity to become ubiquitously distributed brands.
TPB Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 25, 2027 | 2026 (Q4) | 0.35- | 0.42 | ― | ― |
| Nov 09, 2026 | 2026 (Q3) | 0.200.19 | 1.13 | -83.19% (-0.94) | |
| Aug 04, 2026 | 2026 (Q2) | 0.120.18 | 0.79 | -77.22% (-0.61) | |
| May 07, 2026 | 2026 (Q1) | 0.570.60 | 0.79 | -24.05% (-0.19) | |
| Mar 02, 2026 | 2025 (Q4) | 0.870.42 | 0.13 | 223.08% (+0.29) | |
| Nov 05, 2025 | 2025 (Q3) | 0.751.13 | 0.68 | 66.18% (+0.45) | |
| Aug 06, 2025 | 2025 (Q2) | 0.730.79 | 0.68 | 16.18% (+0.11) | |
| May 07, 2025 | 2025 (Q1) | 0.700.79 | 0.63 | 25.40% (+0.16) | |
| Mar 06, 2025 | 2024 (Q4) | 0.680.13 | 0.53 | -75.47% (-0.40) | |
| Nov 07, 2024 | 2024 (Q3) | 0.690.68 | 0.58 | 17.24% (+0.10) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
